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ABSTRACT
The role of lymphocyte antigen 6 complex, locus K (LY6K) in breast cancer 
has been studied, whereas the epigenetic control of LY6K transcription is not 
fully understood. Here, we report that breast cancer patients with increased LY6K 
expression had shorter disease-free and overall survival than the patients with 
low levels of LY6K by multivariate analysis. LY6K also was upregulated in breast 
cancer patients with distant metastases than those without distant metastases, 
downregulating E-cadherin expression. Furthermore, xenograft tumor volumes from 
LY6K knockdown nude mice were reduced than those of mice treated with control 
lentivirus. Interestingly, LY6K has a CpG island (CGI) around the transcription start 
site and non-CGI in its promoter, called a CGI shore. LY6K expression was inversely 
correlated with methylation in not only CGI but CGI shore, which are associated with 
histone modifications. Additionally, LY6K methylation was increased by the PAX3 
transcription factor due to the SNP242 mutation in LY6K CGI shore. Taken together, 
breast cancer risk and metastasis were significantly associated with not only LY6K 
expression, but also methylation of CGI shore which induced by SNP242 mutation. 
Our results suggest that an understanding epigenetic mechanism of the LY6K gene 
may be useful to diagnose carcinogenic risk and predict outcomes of patients with 
metastatic breast cancer.
INTRODUCTION
The relationship between breast cancer and 
epigenetics was first revealed in 1983 [1]. Over the past 
few years, there has been an exponential increase in 
breast cancer epigenetic studies [2]. Epigenetic tools are 
emerging as a new diagnostic and therapy target to treat 
breast cancer. Detection of breast cancer at an early stage 
is the key to successful treatment and patient outcomes 
[3]. Considering the benefits of epigenetics, a change in 
DNA methylation may be regarded as a useful biomarker 
of breast cancer because, compared to other sources such 
as mRNA and protein, DNA is relatively stable and can 
be obtained as cell-free DNA from the blood, ductal 
lavage fluids, nipple aspirate fluids, and fine needle 
aspirates of primary tumors [4-8]. A number of studies 
have reported the ability to detect breast cancer cells 
by epigenetic analysis in fine needle aspirations, nipple 
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aspirates, and ductal lavages [9-12]. Therefore, epigenetic 
alterations such as specific gene DNA methylation, histone 
modifications, or other events hold promise as tools for 
early detection of breast cancer.
The invasiveness and metastatic function of LY6K 
in cancer as a diagnostic biomarker and therapeutic target 
has been elucidated in various cancers such as head and 
neck squamous cell carcinoma, breast cancer, lung and 
esophageal carcinomas, bladder cancer, and esophageal 
squamous cell carcinoma [13-18]. Additionally, LY6K is 
a target for cancer vaccine therapies because stimulating 
cytotoxic T lymphocytes by endogenously expressed 
LY6K presents a specific cytotoxic activity against lung 
and esophageal squamous cell carcinoma [19]. Therefore, 
targeting LY6K epigenetic modification may be a useful 
cancer therapeutic strategy.
In this report, we investigated the relationship 
between chromatin modifications and their association 
with DNA methylation patterns and LY6K expression in 
breast carcinoma and cell lines. First, we found that LY6K 
expression was significantly correlated with overall survival 
(OS) and distant metastasis, while DNA methylation was 
inversely associated with LY6K expression in breast cancer 
cell lines and tumors. In addition, xenograft tumors were 
reduced in nude mice that downregulated LY6K following 
lentivirus treatment. Interestingly, methylation of LY6K 
non-CGI promoter was increased by PAX3 due to the 
SNP242 mutation. These observations highlight a novel 
mechanism of LY6K methylation and expression. Finally, 
this study proposes understanding of epigenetic changes in 
LY6K may contribute to the diagnosis of cancer risk and 
prognosis of patients with breast cancer.
RESULTS
LY6K as an independent prognostic maker for 
metastasis and overall survival in patients with 
breast carcinoma
LY6K immunohistochemical analysis using 144 
clinical samples indicated that LY6K mainly localized 
in the cell membrane and cytoplasm of the tumor cells, 
while peri-tumoral stromal tissue did not expressed LY6K 
(Supplementary Figure S1). LY6K expression significantly 
associated with older patients (P = 0.006) and latent 
metastasis at the distant site (P < 0.001) (Supplementary 
Table S2). In the univariate and multivariate Cox model, 
TNM stage, HER2 expression, and LY6K expression 
were significantly associated with OS, EFS, and DMR 
(Supplementary Table S3 and Table 1). In addition, we 
analyzed the prognostic significance of LY6K expression 
in the subgroups of patients who received adjuvant 
chemotherapy or endocrine therapy, and ER-positivity of 
the tumors (Supplementary Figure S2). Higher levels of 
LY6K without reference to subgroups were independently 
associated with greater risk of death, shorter EFS, and 
greater risk of distant metastatic relapse when compared 
with patients with LY6K-negative tumors (Figure 1A).
LY6K reduces E-cadherin expression in breast 
carcinoma and cancer cell lines
When we further analyzed this set of clinical 
samples, we found that LY6K-positive breast cancer 
tissues presented a lower E-cadherin, an epithelial marker, 
expression level, but E-cadherin expression increased in 
LY6K-negative breast tumor samples (Figure 1B). We 
investigated the relationship between the expression of 
these EMT-related markers and LY6K in breast cancer cell 
lines. Interestingly, we found that E-cadherin expression 
level significantly decreased in LY6K overexpressing cells 
but did not have an effect on vimentin, a mesenchymal 
marker (Figure 1C). Seven of the 12 human breast 
carcinoma cell lines (58%), MCF7-ADR, MDA-MB-157, 
MDA-MB-231, MDA-MB-435, MDA-MB-436, MDA-
MB-468 and SK-BR-3 lines expressed the highest 
level of LY6K mRNA (Supplementary Figure S3). In 
contrast, MCF7, MDA-MB-361, MDA-MB-453, T47D, 
and ZR-75-1 cell lines did not express LY6K mRNA 
(Supplementary Figure S3). We transiently and stably 
knocked down LY6K in the LY6K-positive breast cancer 
cell lines, MCF7-ADR and mouse adapted MDA-
MB-231 cells (MB-231/A), using siRNA and lentivirus, 
respectively. We found that E-cadherin expression was 
induced by LY6K knockdown but vimentin expression 
was not decreased by LY6K knockdown in both MCF7-
ADR and mouse adapted MDA-MB-231 cells (Figure 1C).
Stable knockdown of LY6K inhibited the growth 
of breast cancer xenograft in nude mice
We next determined the effect of LY6K on the 
growth breast cancer xenograft in nude mice using mouse 
adapted MDA-MB-231 cells, called MB-231/A. Cancer 
cell populations can more survive in secondary xenograft 
assay than primary xenograft [20]. As shown in Figure 2A 
mouse adapted MDA-MB-231 cells shows more sharp-
shaped than MB-231. LY6K expression level was stably 
knockdown in lentivirus-treated cells (Figure 2B). 1 × 106 
stable cells were injected into nude mice to establish 
secondary xenograft. At day 33 after injection, lentivirus-
treated stable knockdown of LY6K tumors were smaller 
and grew more slowly as compared with respective control 
tumors transduced with empty lentiviral particles (Figures 
2C and 2D). Immunohistochemistry staining revealed 
that LY6K showed lower levels and the Ki-67 positive 
cells was significantly reduced in LY6K lentivirus-treated 
xenografts (Figure 2E). Also E-cadherin still showed 
significantly higher levels in MB-231/A xenografts of the 
stable LY6K downregulating group (Figure 2F).
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Detection of LY6K methylation in surgical breast 
cancer samples and breast cancer cell lines
We used the UCSC genome browser and the 
online Methprimer software to identify CGI in the 
region around the transcription start site of the LY6K 
(Figure 3A). MCA was performed to assess LY6K 
methylation in CGI shore and bisulfite pyrosequencing 
were performed to confirm the results with selected 
breast tissues and cell lines in both CGI and CGI shore 
regions. An excellent concordance between the results 
obtained by bisulfite pyrosequencing and MCA methods 
was observed. LY6K methylation was analyzed by MCA 
in 30 breast carcinomas and 15 NTL breast tissues. On 
the basis of BSP, NTL, tumor and metastatic tumors 
had 71%, 22% and 11% of 29 CpG sites methylated 
especially CGI shore region had 64%, 26% and 16% 
of 13 CpG sites methylated, respectively, whereas the 
estimated percentage of methylation by MCA was 69%, 
35% and 19% (Figures 3B and 3C). The concordance 
was also breast cancer cell lines with BSP methylation 
of 13 CpG sites within CGI shore demonstrating 18% 
and 21% in LY6K-positive MCF7-ADR and MB-436 
cells, and 60% and 71% in LY6K-negative T47D and 
ZR-75-1 cells, whereas the estimated percentages of 
methylation determined by MCA were 14%, 26%, 68% 
and 85%, respectively (Figures 3D and 3E). Finally, 
we compared LY6K expression levels and methylation 
status in breast cancer subtypes using the public datasets 
obtained from cBioPortal TCGA database (mRNA 
microarray and methylation array HM27) [21, 22]. 
LY6K mRNA expression was higher in triple-negative 
breast cancer subtype (TNBC) as compared with other 
subtypes (Supplementary Figure S5A). Interestingly, 
LY6K methylation and expression were significantly 
negatively correlated not only in TNBC (Pearson’s P 
value = -0.683) but also other subtypes (Supplementary 
Figure S5B).
SNP242 mutation increases DNA methylation 
which suppresses LY6K expression
LY6K mRNA and protein expression were 
markedly increased after 5 µM 5-aza-dC for 72 h, but 
not after TSA treatment, in the hypermethylated LY6K-
negative cell lines MCF7 and T47D (Figure 4A). When 
MCF7 were treated with 5-aza-dC, MSP showed reduced 
intensity of the methylated DNA bands in comparison 
to that in the untreated cell lines, which paralleled the 
increase in amplification products when primers for 
unmethylated DNA were used (Figure 4B). Some breast 
carcinomas and cell lines expressed LY6K, but others 
did not [23]. LY6K-negative cells presented a C to G 
SNP242 substitution on LY6K promoter that creates de 
novo PAX3 binding sites therefore PAX3 transcription 
factor directly bind to LY6K promoter of mutated 
SNP242, which influence AP-1 binding affinity and 
reduce LY6K expression [23]. PAX3 is known to repress 
transcription by selectively binding with heterochromatin 
protein (HP1) and KAP1, which makes closed chromatin 
[24]. We hypothesized that PAX3 transcription factor 
binding, due to the SNP242 substitution, might increase 
LY6K promoter methylation and reduce AP-1 binding 
and LY6K expression. To confirm that PAX3 increases 
DNA methylation on LY6K promoter in LY6K-negative 
MCF7 cells, we analyzed DNA methylation status and 
expression of LY6K after treatment with a PAX3 siRNA. 
PAX3 siRNA treatment, the expression of LY6K was 
Table 1: Multivariate Cox regression analysis for overall survival and event-free survival in breast carcinoma 
patients
Characteristics OS EFS DMR
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
TNM stage I 1 0.021 1 0.056
II 2.853 (0.997-8.166) 0.051 1.605 (0.552-4.664) 0.385
III and IV 5.138 (1.601-16.485) 0.006 3.696 (1.111-12.297) 0.033
HER2 negative 1 0.002 1 0.003
positive 2.664 (1.443-4.919) 2.242 (1.307-3.845)
LY6K negative 1 < 0.001 1 < 0.001 1 < 0.001
low 2.158 (0.820-5.678) 0.119 1.187 (0.552-2.554) 0.661 3.349 (1.079-10.391) 0.036
high 6.333 (2.565-15.641) < 0.001 4.449 (2.256-8.772) < 0.001 7.597 (2.564-22.505) < 0.001
Abbreviations: OS, overall survival; EFS, event-free survival; DMR, distant metastatic relapse; HR, hazard ratio; 95% CI, 
95% confidence interval; HER2, human epidermal growth factor receptor 2.
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Figure 1: Kaplan-Meier survival analysis and LY6K induces metastasis by regulating E-cadherin. A. Overall survival, 
event-free survival, and distant metastatic relapse according to the expression of LY6K in 144 breast carcinoma. B. E-cadherin was 
inversely correlated with LY6K expression in tumor. C. mRNA expression of epithelial (E-cadherin) and mesenchymal (vimentin) markers 
were determined in breast cancer cell lines transfected with LY6K or siRNA or lenti-viral particle. LY6K was normalized by 18s rRNA. All 
graphs show mean ± SD (error bars) of independent experiments. *, P < 0.05, **, P < 0.001, and ***, P < 0.0001.
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restored and methylation determined by MCA was 
shifted to the left compared with control, indicating that 
LY6K promoter was activated by PAX3 siRNA through a 
reduction in methylation (Figures 4C and 4D).
Distinct histone modifications in the LY6K CGI 
shore correlate with LY6K expression status
We performed a ChIP-qPCR analysis of the histone 
tail modifications using several primer sets spanning the 
region of interest and antibodies for both transcriptionally 
active (acH3K9 and H3K4me3) and inactive (H3K9me3 
and H3K27me3) marks of chromatin to characterize the 
chromatin architecture associated with the LY6K promoter 
(Figure 5A). Although both active and inactive marks of 
chromatin are present throughout the LY6K promoter 
region, H3K4me3 active marks were enriched especially in 
the −250 and −100 CGI shore region of the LY6K in MCF7-
ADR cells, which highly express LY6K compared with that 
of the LY6K-negative/low expressing cell lines. Conversely, 
Figure 2: Tumorigenesis effect of LY6K in vivo. A. Cellular morphology of mouse adapted MB-231 cells and protein expression 
level of LY6K. B. Downregulation of LY6K protein was confirmed in passage 3 and 6 treated with LY6K-lentivirus. C. Inhibition of 
the growth of breast cancer xenograft in nude mice by lentiviral transduction of LY6K. D. The size of tumors arising from LY6K stably 
downregulating was significantly lower than those of the control group at 33 days after inoculation. E. Immunohistochemistry analysis of 
lenti-LY6K tumor was inversely correlated with Ki67 as a marker of cell proliferation. (magnification, × 200; scale bar, 100 µm). F. LY6K 
expression was decreased in lenti-LY6K tumors (n=5), whereas E-cadherin increase compared with tumors of control (n=5). *, P < 0.05, 
and **, P < 0.001 significantly different from respective control group.
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H3K27me3 inactive marks were depleted compared with 
that in the LY6K-negative cell lines. However, acH3K9 
and H3K9me3 marks did not show much of a difference 
between the LY6K-positive and LY6K-negative cell lines 
than the difference observed for trimethylation of H3K4 and 
H3K27. Furthermore, we performed MSP analysis using 
bisulfite-modified ChIP DNA samples to examine how 
the active and inactive chromatin marks were distributed 
with respect to the DNA methylation patterns of LY6K 
in the –350 to +100 region (Figure 5B). The ChIP-MSP 
analysis in the MCF7-ADR cell line showed that acetyl-
H3K9 and trimethyl-H3K4 were predominantly associated 
with alleles presenting unmethylated DNA. Trimethyl-
H3K9 and trimethyl-H3K27 were generally associated with 
methylated DNA, but this pattern was less distinct than the 
active marks (Figure 5B).
DISCUSSION
The human LY6K gene is aberrantly expressed in 
various carcinomas and has been identified as a target 
antigen for diagnosis and cancer vaccine therapies. LY6K 
is upregulated in breast cancer tissues compared with NTL 
expression [14]. Moreover, it increases invasion and migration 
of cancerous cells by activating the ERK signaling pathway in 
breast cancer cell lines [18]. These findings suggest that LY6K 
could be associated with tumor progression and metastasis. 
In our study, we found that patients with high levels of 
Figure 3: Methylation of LY6K in breast tumors and cancer cell lines. A. Schematic map of LY6K showing the location of the 
CpG sites, transcription start site, and primers used for BSP (1 and 2), MCA (1) and MSP (1 and 2). B. and D. Bisulfite analysis from NTL, 
breast tumors and metastatic tumors (B) and breast cancer cell lines (D). C. and E. Melting curves and derivative peaks from four from 
NTL, breast tumors and metastatic tumors (C) and cancer cell lines (E).
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LY6K had an aggressive, metastasizing tumors regardless of 
treatment with adjuvant chemotherapy or endocrine therapy, 
and ER-positivity of tumors. In addition, knockdown of LY6K 
delayed tumor progression in secondary xenograft tumors. 
These results suggest that LY6K is an independent prognostic 
marker of breast cancer and metastasis.
EMT is known to be a key process in tumor invasion, 
metastasis, and tumorigenicity. Several EMT-regulating 
markers, including E-cadherin, SNAI1, ZEB1, and 
vimentin are involved in this process [25]. EMT is also 
involved in epithelial breast cancer metastasis, and during 
this transition, cells lose their epithelial characteristics and 
acquire mesenchymal properties [26]. Here, we found that 
LY6K downregulates the expression of E-cadherin in breast 
cancer cells, carcinomas and xenograft mice, whereas does 
not increase vimentin. Loss of E-cadherin is considered 
a fundamental event in EMT, thus our finding suggests 
that LY6K activates EMT initiation, inducing metastasis. 
Together, these data indicate that LY6K functions as an 
upstream component of the metastasis signaling network that 
can suppress E-cadherin expression at the transcription level.
Chromatin structure, including DNA methylation, 
histone variants and modifications, and nucleosome 
positioning as well as non-coding regulatory RNAs 
are important in the cancer epigenetic pathway [27]. 
Interestingly, only about 70% of human genes contain 
a CGI promoter and only 6.8% of CpGs reside within 
CGIs, many potentially informative CpG sites remain to 
be examined [28, 29]. A recent study showed that DNA 
methylation directly silences genes with non-CGI promoters 
and contributes to establishing tissue-specific methylation 
patterns [30]. Furthermore, tissue- and cancer-specific 
differentially methylated regions occur more frequently 
within CGI shores than within CGIs themselves, suggesting 
the involvement of CGI shore in methylation during tissue 
differentiation, epigenetic reprogramming and cancer [31, 
32]. In this study, LY6K gene expression was altered by 
DNA methylation of not only the LY6K CGI but also non-
CGI promoter, the CGI shore. Our data suggested that 
methylation pattern of LY6K is useful biomarker of cancer 
because LY6K expression was cancer-specifically decreased 
by CGI shore methylation.
Interestingly, LY6K expression was lower in the 
SNP242 mutation which creates de novo PAX3 transcription 
factor binding sites in breast cancer cell lines [23]. PAX3 
reported as a key factor for normal development and 
tumorigenesis, and a transcription repressor that binds with 
HP1 and KAP1, which closed chromatin [24]. We found 
that PAX3 binding sites, created by SNP242, differentially 
increase LY6K promoter methylation, which in turn 
influences migration of breast cancer cells [23]. Moreover, 
a potential correlation between DNA methylation status and 
Figure 4: Pax3 inhibits LY6K expression by regulating methylation. A. LY6K expression was analyzed by qRT-PCR and western 
blotting before and after stimulating the MCF7 and T47D cell lines with 5-aza-dC and/or TSA. 18s rRNA and β-actin expression were analyzed 
as controls. B. MSP analysis of the LY6K CGI shore and CGI in MCF7 and T47D cell lines before and after stimulation with 5-aza-dC and/
or TSA. C. Expression level of Pax3 and LY6K after siRNA transfection normalized with 18s rRNA. D. MSP analysis and melting curves 
from Pax3 siRNA treated cell lines. All graphs show mean ± SD (error bars) of three independent experiments. *, P < 0.05, and **, P < 0.001.
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SNP242 status was found in breast cancer cell lines [23]. 
Based on these findings, we can predict LY6K methylation 
status by determining SNP242 status. Taken together, our 
results indicate that LY6K aberrant expression results from 
the aberrant methylation of LY6K promoter, induced by de 
novo PAX3 binding sites.
Additionally, LY6K gene expression was 
activated or inhibited by trimethylation of H3K4 or 
H3K27 histone modification around the transcription 
start site, respectively. These results suggest that H3K4 
trimethylation may be important in determining LY6K 
expression, whereas H3K27 trimethylation may be 
important for LY6K repression. This analysis confirmed 
that active chromatin marks are associated with 
unmethylated DNA, whereas inactive chromatin marks 
are associated with methylated DNA. Taken together, our 
Figure 5: Histone modification and associated-DNA methylation patterns of LY6K. A. ChIP qPCR was performed using the 
four primer sets listed in Supplementary Table S1 in MCF7, T47D, MCF7-ADR and MDA-MB-231 cell lines. Occupancy of each of the 
chromatin marks: acetylation of histone H3K9 (H3K9ac), trimethylation of histone H3K4 (H3K4me3), trimethylation of histone H3K9 
(H3K9me3) and trimethylation of histone H3K27 (H3K4me3). B. ChIP-MSP analysis around LY6K transcription start site in MCF7, T47D, 
MCF7-ADR and MDA-MB-231 cells using MSP1 and MSP2 primers.
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data indicate that the epigenetic activation, determined by 
the presence of active chromatin marks on unmethylated 
DNA, allows LY6K continued expression.
Subsequently, we confirmed the relationship 
between DNA methylation and histone modification 
within the LY6K CGI and CGI shore. In particular, the 
chromatin was open in the functional LY6K promoter 
region, LY6K CGI shore, which is essential for gene 
activation. In addition, the CpG site within this region 
was hypomethylated. These observations indicate that 
the AP-1 transcription factor preferentially binds to the 
LY6K promoter and can activate the gene (Figure 6). 
The CpG site within the closed chromatin region showed 
a hypermethylated pattern, suggesting that LY6K 
gene expression in cancer can be predicted using DNA 
methylation status and a chromatin mark in the functional 
5′CGI shore of LY6K (Figure 6). These results suggest 
that aforementioned epigenetic features of LY6K might be 
specific to breast tissue and breast cancer. Taken together, 
epigenetic alterations, particularly DNA methylation of 
the LY6K CGI shore and CGI, may contribute to LY6K 
activation in breast cancer.
In this study, we identified and validated in both 
cellular models and clinical samples that LY6K is associated 
with the presence of distant metastasis and patient survival. 
In addition, knockdown of LY6K delayed tumor progression 
in xenograft tumors. We further showed that LY6K aberrant 
expression is the result of DNA methylation and histone 
modifications in LY6K CGI shore and CGI. We elucidated 
that PAX3 binds to LY6K promoter binding sites created 
by SNP242 and suppresses LY6K expression through the 
regulation of DNA methylation.
Figure 6: Dynamic epigenetic modification of LY6K influences the LY6K gene activity. A. In LY6K-positive cells, methylation 
of the histone H3 tail, lysine 4, and demethylation of DNA, which contribute to a more open chromatin conformation that allows RNA 
polymerase II (Pol II) to bind to the LY6K promoter. B. Because of the presence of trimethylated histone K9 and K27 and methylated DNA 
caused by SNP242 mutation, chromatin is in a closed conformation in LY6K negative cells that blocks access to key transcription factors.
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In conclusion, our findings show that LY6K is 
frequently activated by CGI shore hypomethylation and 
active histone marks in breast carcinomas. High levels 
of LY6K expression induce a more aggressive and 
metastatic phenotype. In addition, LY6K methylation 
might be an independent prognostic marker in breast 
carcinoma and may be useful for selecting patients with 
higher risk of recurrence, death, and metastasis and for 
chemotherapy response. Targeting LY6K methylation 
might be a potential strategy for treating patients with 
hypomethylated tumors, although further investigation in 
this area is needed.
MATERIALS AND METHODS
Patients and samples
The original microscopic slides, paraffin-embedded 
tissue samples, and clinical information from 144 female 
patients with breast carcinoma diagnosed between January 
1997 and August 2002 were obtained for this study. The 
patients underwent the modified radical mastectomy or 
breast conserving surgery in Chonbuk National University 
Hospital. Among the 144 patients, 120 patients received 
post-operative endocrine therapy, 128 patients received 
adjuvant chemotherapy, and 109 patients received both 
endocrine therapy and chemotherapy. The pathologic 
features and tumor stage were reviewed by two pathologists 
(Jang KY and Kim KM) according to the World Health 
Organization Classification [20] and the 7th edition of the 
American Joint Committee on Cancer staging system [21]. 
This study was approved by the Institutional Reviewer 
Board of Chonbuk National University Hospital (IRB 
number: 2013-08-016). Informed consent was provided 
according to the Declaration of Helsinki.
Immunohistochemical staining and 
immunohistochemical scoring for tissue 
microarrays
Immunohistochemical staining for LY6K (1:250, 
Sigma-Aldrich, St. Louis, MO, USA) was performed on 
tissue microarray blocks with 3.0 mm sized core. Briefly, 
one core per case was arrayed in a tissue microarray. 
The antigen retrieval procedure was performed with 
a microwave oven for 20 min in pH 6.0 sodium citrate 
buffer. The scoring for LY6K immunostaining was 
performed by two pathologists (Jang KY and Kim KM) by 
consensus without knowledge of the clinicopathological 
information. LY6K immunostaining was evaluated 
to estimate the positivity of tumor cells. The staining 
intensity was scored as 0 (no staining), 1 (weak staining), 
2 (moderate staining), and 3 (strong staining). The area of 
staining was evaluated as 0 (no stained cells), 1 (1–10% of 
the cells stained positive), 2 (11–33% of the cells stained 
positive), 3 (34–66% of the cells stained positive), and 4 
(67–100% of the cells stained positive). Thereafter, the 
sum of intensity score and proportion score was used for 
further analysis. The maximum sum score was seven and 
the minimum sum score was zero.
Cell culture and treatment
Human breast carcinoma MCF7/ADR cell was 
provided by Dr. YM Park (Roswell Park Cancer Institute, 
Buffalo). And MCF7, MDA-MB-231, MDA-MB-435s, 
MDA-MB-453, MDA-MB-468, SK-BR-3 cells were 
obtained from Sapporo Medical University. These cell lines 
were tested using short tandem repeat markers for DNA 
fingerprinting analysis (Korean Cell Line Bank). Other 
human breast carcinoma T47D, ZR-75-1, MDA-MB-157, 
MDA-MB-361, and MDA-MB-436 cells were purchased 
from ATCC (Manassas, VA). Mouse adapted MDA-
MB-231 cells were obtained from primary tumor of MDA-
MB-231 xenograft mice. Breast cancer cells and MDA-
MB231/A were grown in Dulbecco’s Modified Eagle’s 
Medium (WelGENE Inc., Deajeon, Korea) containing 10% 
fetal bovine serum (WelGENE) and maintained at 37°C in 
a humidified atmosphere with 5% CO
2
 and 95% air. Cells 
were seeded at 5 × 105 cells on 60 mm dishes 24 h prior 
to treatment. The cells were treated every day with 2 or 5 
µM 5-aza-2′-deoxycytidin (5-aza-dC; Sigma-Aldrich, St. 
Louis, MO, USA) for 72 h to block CpG methylation and/
or followed by treatment with 100 nM trichostatin A (TSA; 
Sigma) for 6 h to inhibit histone deacetylation.
Establishment of stable cell lines expressing 
siLY6K
The piLenti-siLY6K (LV014) and lentiviral 
packaging plasmids (LV003) were purchased from Applied 
Biological Materials, Inc (abm®) and cotransfected into 
HEK293T cells following the manufacturer’s protocol 
using LentiFectin transfection reagent (G074). The 
lentiviruses in the supernatant was collected, centrifuged 
and used to infect mouse adapted MDA-MB-231 cells. 
After puromycin selection for 2 to 4 weeks, stable clones 
were obtained and subsequently confirmed by qRT-PCR 
and western blotting.
Preparation of breast cancer xenograft mice
All studies involving the use of nude mice were 
approved by the Animal Care and Use Committee of 
Yonsei University Medical School (2014-0348) and 
performed in specific pathogen-free facilities and under 
conditions in accordance with the Guidelines for the 
Care and Use of Laboratory Animals of YUMS. Mice 
were inoculated subcutaneously with 1 × 106 stable 
MDA MB-231-(vector), MDA MB-231-(shLY6K) cells 
into each flank under 150 µL of saline/zoletil/rompun 
(7:1:1) anesthesia. Mice were randomized into groups 
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(n = 5 per group). From palpable tumor formation until 
termination, tumor sizes were measured every 2 to 3 days 
using calipers, and tumor volume was calculated with 
the following formula: length × width2 × 0.5236. Mice 
were sacrificed in a 7.5% CO
2
 chamber, and tumors were 
harvested for immunohistochemical and other analyses.
Total RNA isolation and qRT-PCR
Cellular RNA was isolated from breast cancer 
cell lines using a NucleoSpin® DNA/RNA/Protein kit 
(MACHEREY-NAGEL, Düren, Germany), according 
to the manufacturer’s instructions. RNA (2–5 μg) was 
reverse transcribed to cDNA using the M-MLV Reverse 
Transcription kit (Promega, Madison, WI, USA). About 1 
μL aliquot of cDNA was used as the template to amplify 
a specific fragment in a 30 μL reaction mixture under the 
following conditions: denaturation at 94ºC for 5 min, 30 
cycles at 94ºC for 30 s, 58ºC for 30 s and 72ºC for 30 s, and 
then an extension at 72ºC for 5 min. And qRT-PCRs were 
performed with LightCycler 96 SYBR Green I Master mix 
(Roche, Basel, Switzerland) on an ABI Real-time PCR 7500 
system using human 18s rRNA as endogenous control. All 
reactions were performed in triplicate.
DNA isolation and bisulfite treatment
Genomic DNA was extracted from breast cancer 
cell lines using a NucleoSpin® total DNA/RNA/Protein 
kit (MACHEREY-NAGEL), following the manufacturer’s 
instructions. Unmethylated cytosine bases of genomic 
DNA (500 ng) were converted to uracil using the EZ DNA 
Methylation-Gold kit (Zymo Research, San Francisco, 
CA, USA).
Bisulfite pyrosequencing
Sequences after bisulfite treatment were analyzed 
using Pyrosequencing™ (PyroMark ID System, Biotage, 
Stockholm, Sweden) technology. Primers selected 
for amplification were designed using PyroQ-CpG™ 
Software (Biotage) and listed in Supplementary Table S1. 
Amplification was performed using 100 ng of total DNA 
in a 50 µL PCR reaction mix. Samples were denatured for 
5 min at 94°C followed by 44 cycles of amplification at 
94°C for 30 s, 55°C for 1 min, and then 72°C for 90 s. A 
30 µL aliquot of PCR product was used for immobilization 
by streptavidin sepharose beads (Streptavidin Sepharose™ 
high performance, GE Healthcare Bio-Science AB, Uppsala, 
Sweden) and the single-stranded DNA was incubated with 
the biotinylated sequencing primer at 95°C for 10 min.
Melting curve analysis (MCA)
Methylated and unmethylated DNA was purchased 
from Qiagen (Valencia, CA, USA) as a positive and 
negative control respectively. Methylation standards 
(100%, 75%, 50%, 25%, and 0%) were prepared by 
mixing the positive and negative controls accordingly. 
Primers used for MCA were designed using the Sequenom 
(http://www.epidesigner.com) listed in Supplementary 
Table S1. Bisulfite converted DNA was amplified using 
the MCA primer sets with LightCycler 96 SW 1.1 (Roche) 
in the presence of LightCycler 96 SYBR Green I Master 
(Roche). The PCR reactions were cycled for 45 cycles of 
at 94ºC for 30 s, 54ºC for 30 s and 72ºC for 30 s, and then 
an extension at 72ºC for 3 min. After the amplification, 
temperature was gradually increased from 65 to 95°C to 
obtain the melting curves. The melting curve peaks were 
plotted by using the LightCycler 96 software (Roche) 
and by calculating the negative derivative of fluorescence 
over temperature. The area under the curve (AUC) was 
quantified for the melting peak corresponding to the 
unmethylated and methylated alleles. In addition, the 
percentage of DNA methylation was estimated on the 
basis of the linear regression between the AUC values and 
the methylation standards (Supplementary Figure S4).
Methylation-specific PCR (MSP)
Primers specific for LY6K unmethylated and 
methylated alleles were used to amplify bisulfite-treated 
DNA. Methylation specific PCR primers were designed 
for the LY6K promoter and for parts of LY6K gene body, 
from −300 to +1000. The primer sequences are shown in 
Supplementary Table S1 and their location is presented 
in Supplementary Figure S4. MSP was conducted with 1 
µL bisulfite-modified genomic DNA that was mixed with 
10× MSP buffer (166 mM (NH
4
)
2
SO4, 670 mM Tris (pH 
8.8), 67 mM MgCl
2
 and 100 mM 2-mercaptoethanol), 
25 mM dNTP, MSP forward and reverse primers, and 
HotStar Taq® Plus DNA polymerase (Qiagen) using the 
following cycling conditions: denaturation at 94°C for 15 
min, followed by 35 cycles at 94°C for 30 s, 55°C for 30 
s, and 72°C for 1 min, with a final extension at 72°C for 
5 min. The MSP bands were detected on 2% agarose gel 
electrophoresis.
Western blotting
Proteins extracts were prepared using a 
NucleoSpin® DNA/RNA/Protein kit (MACHEREY-
NAGEL), following the manufacturer’s protocol. 
Immunoblotting was carried out according to a previously 
described method using anti-LY6K (I-14; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) and anti-β-actin 
(Bethyl Laboratories, Inc. Montgomery, TX, USA) 
antibodies [23].
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the imprint 
chromatin immunoprecipitation kit (CHP1, Sigma-
Aldrich) following the manufacturer’s instructions. 
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The sonicated DNA was incubated with anti-IgG 
(Millipore, Milford, MA, USA) as a negative control, 
anti- H3K9ac (Millipore), anti-H3K4me (Millipore), 
anti-H3K9me3 (Abcam, Cambridge, MA, USA) and anti-
H3K27me3 (Millipore) at 37ºC for 90 min. The purified 
DNA was amplified using specifically designed real-time 
ChIP PCR primers spanning the region −300 to +1000 of 
LY6K (Supplementary Table S1).
ChIP-MSP
Approximately 25 μL of the 50 μL ChIP DNA 
product was bisulfite modified as described above. MSP 
was performed using the LY6K MSP primers listed in 
Supplementary Table S1.
Statistical analysis
LY6K immunohistochemical expression was 
grouped as negative, low-expression, or high-expression 
by receiver operating characteristic curve analysis for the 
prediction of the risk of death (Supplementary Figure S1). 
The cut-off point between high-LY6K and low-LY6K 
was seven and the cut-off point between low-LY6K and 
LY6K-negative was four (LY6K-negative, score 0–3; 
low-LY6K, score 4–6; high-LY6K, score 7). To compare 
the association between clinicopathologic variables and 
LY6K expression, Pearson’s chi-square test were used. 
The prognostic significance of the LY6K expression in 
patients with breast carcinoma was analyzed by evaluating 
OS, event-free survival (EFS), and distant metastatic 
relapse (DMR). The follow-up end point was the date of 
the last contact or the date of death through December 
2012. Cox proportional hazards regression analyses and 
Kaplan-Meier survival analysis were performed using 
SPSS software (version 19.0, SPSS, Chicago, IL, USA). 
Student’s t-tests were used to evaluate differences using 
GraphPad Prism 5 Software (GraphPad Software Inc., 
San Diego, CA, USA). The non-parametric, Pearson’s and 
Spearman’s rank test, was used to examine the correlation 
between expression and methylation of LY6K. P values 
< 0.05 were considered statistically significant (n = 3 for 
each experiment).
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